11:56 AM EST, 11/10/2025 (MT Newswires) -- Novartis ( NVS ) said Monday it has opened a new 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California.

The facility, which will manufacture RLTs, a form of precision medicine that combines a tumor-targeting molecule (ligand) with a therapeutic radioisotope, can begin commercial operations once it is approved by the Food and Drug Administration, Novartis ( NVS ) said.

The facility is part of Novartis' ( NVS ) planned $23 billion investment in US infrastructure over the next five years, the company said.

Price: 126.57, Change: +0.22, Percent Change: +0.17